Intermittent preventive treatment in infants (IPTi) for malaria provides preventive antimalarial medicine to children under 12 months old. It is among the most promising programs we’ve identified in our active pipeline of new interventions. It’s also underutilized, and the population it targets is especially vulnerable to malaria. That implies potential to open up large amounts of room for more funding if IPTi begins to be used more widely—our crude estimate is between $50 million and$200 million globally once it’s scaled—which is something we’re increasingly thinking about as we aim to direct $1 billion in cost-effective funding by 2025. In September 2021, we recommended a small grant to Malaria Consortium and PATH to assess the feasibility and cost-effectiveness of implementing IPTi at national scale in two countries. We’re hopeful that this scoping exercise will answer some of our many open questions about IPTi, and that this intervention continues to look promising as we learn more. Read More # Our recommendations for giving in 2021 You can have a remarkable impact by supporting cost-effective, evidence-based charities. Just looking at the approximately$100 million GiveWell had discretion to grant in 2020—a subset of all the money we directed to the charities we recommend—the impact of our donors is impressive. We estimate these grants will:

• Save more than 24,000 lives
• Treat over 6 million children with a full course of antimalarial medication
• Provide vitamin A supplementation to over 8.6 million children
• Deliver over 4.4 million long-lasting insecticide-treated nets (LLINs) to protect against malaria
• Vaccinate 118,000 children
• Treat over 11.4 million children for parasitic worms

# Initial thoughts on malaria vaccine approval

The World Health Organization (WHO) recently recommended the widespread use of the malaria vaccine RTS,S/AS01 for children. It provides an additional, effective tool to fight malaria. This is great news!

We’ve been following this vaccine’s development for years and, in the last few months, have been speaking with organizations involved in its development and potential wider rollout.

Our work on RTS,S (and other malaria vaccines) is ongoing, and we might significantly update our views in the near future. But because we’ve been following its progress, we’re sharing some initial thoughts.

# Our recommendations for giving in 2020

You can have a major, positive impact today by choosing to support organizations backed by strong evidence: our top charities.

We recommend the nonprofits that offer the most impact per dollar we’re aware of. In fact, we estimate that you can save a life by donating $3,000-$5,000 to our top recommendation.[1]

If you’re a longtime donor, you’ll recognize most of this year’s top charities. You may even wonder why our list hasn’t changed much. However, a tremendous amount of research—truly thousands of hours—has been done to ensure that these organizations continue to meet our high standards. And although there are many familiar names, one is entirely new: New Incentives.

We’re proud to share our recommendations and grateful to you for considering supporting them. We hope you’ll read on!

# Why we’re excited to fund charities’ work a few years in the future

We recently spoke with someone who wanted to donate to a GiveWell top charity. They were interested in getting the funding “out the door” and to program participants as quickly as possible.

But our top choice for funding today is Malaria Consortium’s seasonal malaria chemoprevention program—for work it expects to complete in 2022.[1] The potential donor was puzzled. Shouldn’t we prioritize an organization that needs the money sooner?

We often recommend donations today that support programs a few years from now. This probably diverges from many people’s intuitions about getting funding out the door as soon as possible.

# Allocation of discretionary funds from Q4 2019

We recently allocated donations made from October through December 2019 to “Grants to recommended charities at GiveWell’s discretion.” We granted $11.9 million to Malaria Consortium’s seasonal malaria chemoprevention program and$1.5 million to Helen Keller International’s vitamin A supplementation program.

We allocate donations to “Grants to recommended charities at GiveWell’s discretion” (discretionary funds) quarterly, according to where we see the highest-priority funding needs. Malaria Consortium’s seasonal malaria chemoprevention (SMC) program and Helen Keller International (HKI)’s vitamin A supplementation (VAS) program had the top-priority needs among our top charities at the time we made this decision.

Malaria Consortium provides preventive anti-malarial medication to young children during the time of year when malaria transmission is highest. HKI supports provision of vitamin A supplements to young children, which reduces their risk of dying of infectious disease.[1] We estimate that the combined discretionary grants to these organizations will save 5,600 lives.[2]

In this post, we discuss:

• Our process for deciding where to allocate discretionary funds. (More)